How far down to push the LDL cholesterol? PCSK9 where statins fail

被引：0
作者：
Simko, V [1 ]
Ginter, E. [2 ]
机构：
[1] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
[2] Slovak Med Univ, Bratislava, Slovakia
来源：
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY | 2016年 / 117卷 / 04期
关键词：
ATHEROSCLEROSIS;
D O I：
10.4149/BLL_2016_036
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：193 / 194
页数：2
相关论文
共 50 条
  • [1] Beyond LDL Cholesterol, a New Role for PCSK9
    Akram, Omar N.
    Bernier, Adeline
    Petrides, Francine
    Wong, Gida
    Lambert, Gilles
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (07) : 1279 - 1281
  • [2] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [3] LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors
    Luscher, Thomas F.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1337 - 1340
  • [4] PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Luquero, Aureli
    Badimon, Lina
    Borrell-Pages, Maria
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [5] Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
    van der Tuin, Sam J. L.
    Kuhnast, Susan
    Berbee, Jimmy F. P.
    Verschuren, Lars
    Pieterman, Elsbet J.
    Havekes, Louis M.
    van der Hoorn, Jose W. A.
    Rensen, Patrick C. N.
    Jukema, J. Wouter
    Princen, Hans M. G.
    van Dijk, Ko Willems
    Wang, Yanan
    JOURNAL OF LIPID RESEARCH, 2015, 56 (11) : 2085 - 2093
  • [6] PCSK9 and atherosclerosis: Looking beyond LDL regulation
    Ragusa, Rosetta
    Basta, Giuseppina
    Neglia, Danilo
    De Caterina, Raffaele
    Del Turco, Serena
    Caselli, Chiara
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (04)
  • [7] Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration
    Miyazawa, Haruna
    Honda, Tomoyuki
    Miyauchi, Sayuri
    Domon, Hisanori
    Okui, Takafumi
    Nakajima, Takako
    Tabeta, Koichi
    Yamazaki, Kazuhisa
    CLINICA CHIMICA ACTA, 2012, 413 (1-2) : 154 - 159
  • [8] Back to Basics: PCSK9 as a New Target for the LDL Receptor
    Corral, Pablo
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2014, 102 (01) : E5 - E8
  • [9] Exercise training increased gene expression of LDL-R and PCSK9 in intestine: link to transintestinal cholesterol excretion
    Farahnak, Zahra
    Chapados, Natalie
    Lavoie, Jean-Marc
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2018, 37 (03) : 309 - 317
  • [10] The Clinical Safety, Pharmacokinetics, and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor
    Johns, Douglas G.
    Almonte, Yuddy
    Bautmans, An
    Campeau, Louis-Charles
    Cancilla, Mark T.
    Chapman, Justin
    Crevecoeur, Inne
    Guetschow, Erik D.
    Kauh, Eunkyung A.
    Lai, Eseng
    Lanning, Christine L.
    Lee, Anita Y.
    Li, Li
    Mitchel, Yale B.
    Stoch, S. Aubrey
    Van Dyck, Kristien
    Vanhoutte, Frederic P.
    Volckaert, Bram
    Wolford, Dennis G.
    Wood, Harold B.
    Xu, Andy
    Zhao, Tian
    Zhou, Susan
    Banka, Puja
    CIRCULATION, 2021, 144 (25) : E573 - E573
12345